Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 10 Mar 2026 | Jan Hendrik Dopheide Cabinet member | Introductory meeting / competitiveness and trade policy | SRC |
| 10 Mar 2026 | Jan Hendrik Dopheide Cabinet member | Introductory meeting / competitiveness and trade policy | — |
| 04 Dec 2025 | Tomas Baert Cabinet member | Presentation of the three work streams of the EU-Japan Business Round Table | SRC |
| 04 Dec 2025 | Tomas Baert Cabinet member | Presentation of the three work streams of the EU-Japan Business Round Table | — |
| 06 Nov 2025 | Arthur Corbin Cabinet member | Exchange of views on industrial policies | — |
| 06 Nov 2025 | Arthur Corbin Cabinet member | Exchange of views on industrial policies | SRC |
| 20 Oct 2025 | Eva Schultz Cabinet member | Meeting on the fertility matters in relation to EU Gender Equality and Demography Strategies | — |
| 20 Oct 2025 | Eva Schultz Cabinet member | Meeting on the fertility matters in relation to EU Gender Equality and Demography Strategies | SRC |
| 15 Oct 2025 | Alexandr Hobza Cabinet member | Exchange of views on regulatory environment for Life Sciences Manufacturing sector | — |
| 15 Oct 2025 | Alexandr Hobza Cabinet member | Exchange of views on regulatory environment for Life Sciences Manufacturing sector | SRC |
| 01 Oct 2025 | Sonia Vila Nunez Cabinet member | To formally present and discuss the Movement +Fertility, and the Portuguese Manifesto for reproductive equality and a sustainable future. | — |
| 01 Oct 2025 | Sonia Vila Nunez Cabinet member | To formally present and discuss the Movement +Fertility, and the Portuguese Manifesto for reproductive equality and a sustainable future. | SRC |
| 09 Sept 2025 | Boriša Falatar Cabinet member | gender equality and strengthening health preparedness | SRC |
| 09 Sept 2025 | Boriša Falatar Cabinet member | gender equality and strengthening health preparedness | — |
| 10 Jul 2025 | Zaneta Vegnere Cabinet member | competitiveness | SRC |
| 10 Jul 2025 | Olivér Várhelyi Commissioner | Exchange of views on the EU pharma and health policy matters | SRC |
| 10 Jul 2025 | Olivér Várhelyi Commissioner | Exchange of views on the EU pharma and health policy matters | — |
| 10 Jul 2025 | Zaneta Vegnere Cabinet member | competitiveness | — |
| 03 Jul 2025 | Jana Dabbelt Cabinet member | • Intro to company • pharma legislation and CMA • UWWTP and health-specific policies (mental health, fertility, cancer and cardiovascular health) | — |
| 03 Jul 2025 | Jana Dabbelt Cabinet member | • Intro to company • pharma legislation and CMA • UWWTP and health-specific policies (mental health, fertility, cancer and cardiovascular health) | SRC |
| 01 Jul 2025 | Giulia Del Brenna Head of Unit | The specifics of life science-related upcoming initiatives, including the new Bioeconomy Strategy, the Biotech Act, and Life Science Strategy. | — |
| 01 Jul 2025 | Giulia Del Brenna Head of Unit | The specifics of life science-related upcoming initiatives, including the new Bioeconomy Strategy, the Biotech Act, and Life Science Strategy. | SRC |
| 27 Jun 2025 | Kevin Barrett Cabinet member | Exchange of views on issues relating to competitiveness and corporate sustainability | — |
| 27 Jun 2025 | Kevin Barrett Cabinet member | Exchange of views on issues relating to competitiveness and corporate sustainability | SRC |
| 27 Jun 2025 | Michael McGrath Commissioner | Exchange of views on issues relating to competitiveness and corporate sustainability | — |
Mission & Goals
Merck, a leading science and technology company, generated total revenues of €22,2 billion in 2022 with its divisions Healthcare, Electronics and Life Science. More than 64,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent stakes, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are the United States and Canada. Here Merck operates as EMD Serono in the Biopharma business, MilliporeSigma in the Life Science business, and as EMD Performance Materials in the Performance Materials/Electronics business.
EU Legislative Interests
Clean Industrial Deal, EU Economic Security Strategy, EU Competitiveness, Single Market Completion and all relevant policies/initiatives such as: Chemicals Strategy for Sustainability - REACH revision, Industrial Emissions Directive, Clean Air and Water, Fit-for-55, CLP regulation, Circular Economy policies, PFAS, CBAM Raw-Materials Act Digital Policies (i.e. EU Chips-Act, EU AI Act, EHDS) Trade policies (eg Global Gateway, customs regulations, TTC developments) Sustainable Finance (eg Taxonomy) Omnibuses for simplification Pharmaceutical Strategy and Health Care related policies. Intellectual Property (IP) Package Life Science related policies such as Medicinal Products Directive. Alternative approached to Animal testing Sanctions Packages on Russia etc.
Communication Activities
2024: Sponsoring of a Talk in Brussels on the topic of EU Competitiveness, with representatives of EU parliament, EU Commission and other stakeholders.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Merck is a member of CEFIC (EU), EFPIA (EU), EBE - European Biopharmaceutical Enterprises (EU), EuropaBio, BVAC (DE with EU-office), VCI (DE) and its sub-state organisations such as LV Hessen, and DIB (Deutsche Industrievereinigung Biotechnologie), Bundesverband der deutschen Industrie (BDI), Verband forschender Arzneimittelhersteller (DE), World Economic Forum (WEF), Bitkom (DE), European Round Table for Industry (ERT), Cosmetics Europe, EUCCC (European Chamber of Commerce), ACATECH and various other sectoral organisations mainly at respective national/regional levels in the countries such as European General Counsel Association (UK), European Process Safety Center (UK), European Centre for Ecotoxicology and Toxicology of Chemicals (BE), European Partnership for Alternative Approaches to Animal testing (EPAA)
Organisation Members
see above
Additional Information
Costs increased in 2024 due to the high number of important files that required more work with EU Institutions (General Pharmaceutical Legislation, Green Deal, PFAS, Chips and AI,...), and post-election intensive activities